Erratum. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45(Suppl. 1):S144-S174.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed, 4 syntheses or guidelines pooled it.

1. Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline.BMJ (Clinical research ed.) · 2025
   Guideline
2. Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes.The Cochrane database of systematic reviews · 2023
   Pooled it
3. [Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (update 2023)].Wiener klinische Wochenschrift · 2023
   Guideline
4. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis.Frontiers in endocrinology · 2022 · on this map
   Pooled it
5. The Prevalence of Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes in Jordan: The PACT-MEA Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
   Article
6. A machine learning approach to predict positive coronary artery calcium scores in individuals with diabetes: a cross-sectional analysis of ELSA-Brasil baseline data.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025
   Article
7. Molecular Pathways in Diabetic Cardiomyopathy and the Role of Anti-hyperglycemic Drugs Beyond Their Glucose Lowering Effect.Journal of lipid and atherosclerosis · 2025
   Review
8. Risk of Cardiovascular Disease according to Baseline Low-Density Lipoprotein Cholesterol Level in Different Age Groups in Korean Diabetes Population: A Cohort Study.Diabetes & metabolism journal · 2024
   Article
9. The Acute Coronary Syndrome Risk in Medically Managed Subjects with Type 2 Diabetes Mellitus - Is the ASCVD Risk Score Failing Here?Journal of the ASEAN Federation of Endocrine Societies · 2024
   Article
10. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.Cardiovascular diabetology · 2023
    Review
11. Comparison of on-Statin Lipid and Lipoprotein Levels for the Prediction of First Cardiovascular Event in Type 2 Diabetes Mellitus.Diabetes & metabolism journal · 2023
    Article
12. Trends in glycemic, blood pressure, and lipid control in adults with diabetes in Switzerland: the CoLaus|PsyCoLaus Study.BMJ open diabetes research & care · 2023
    Article
13. Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus.Diabetes & metabolism journal · 2023
    Review
14. Levels and correlates of risk factor control in diabetes mellitus -ELSA-Brasil.Diabetology & metabolic syndrome · 2023
    Article
15. Trends in the prevalence of elevated cardiovascular risk and the control of its risk factors Among US adults, 2001-2020.Frontiers in cardiovascular medicine · 2023
    Article
16. Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement.Diabetes & metabolism journal · 2023
    Review
17. Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement.Diabetes & metabolism journal · 2023
    Review
18. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.Mayo Clinic proceedings. Innovations, quality & outcomes · 2022
    Review
19. Blood Pressure Control in Patients with Diabetic Kidney Disease.Electrolyte & blood pressure : E & BP · 2022
    Review
20. Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium-Glucose Co-transporter-2 Inhibitors.TouchREVIEWS in endocrinology · 2022
    Review

Corrections and comments

• Erratum for
  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.2022

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.